Who
Robin Kramer
Director
Company insider
Files Form 4 as: Director, Armata Pharmaceuticals; Chief Financial Officer, Biogen; Sr VP Chief Accounting Officer, Hertz Global Holdings; Sr VP, ChiefAccountingOfficer, Herc Holdings.
In numbers
- Trades disclosed
- 154
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $183K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 17 Feb 2015
- Last trade
- 9 Mar 2026
- Last filed
- 11 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Mar 2026filed 11 Mar 2026 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,640 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,640 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,450 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,450 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —789 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $55K273 at $201.18 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —703 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —789 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —703 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,511 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $42K207 at $201.18 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —3,511 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $214K1,063 at $201.18 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —789 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code M | —703 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —789 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $55K273 at $201.18 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —703 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $42K207 at $201.18 | filing |
| 6 Feb 2026filed 10 Feb 2026 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —3,511 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.